The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741
Abstract
Purpose: Using a 2 × 2 factorial design, we studied the adjuvant chemotherapy of women with axillary node–positive breast cancer to compare sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) with concurrent doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) for disease-free (DFS) and overall survival (OS); to determine whether the dose density of the agents improves DFS and OS; and to compare toxicities. Patients and Methods: A total of 2,005 female patients were randomly assigned to receive one of the following regimens: (I) sequential A × 4 (doses) → T × 4 → C × 4 with doses every 3 weeks, (II) sequential A × 4 → T × 4 → C × 4 every 2 weeks with filgrastim, (III) concurrent AC × 4 → T × 4 every 3 weeks, or (IV) concurrent AC × 4 → T × 4 every 2 weeks with filgrastim. Results: A protocol-specified analysis was performed at a median follow-up of 36 months: 315 patients had experienced relapse or died, compared with 515 expected treatment failures. Dose-dense treatment improved the primary end point, DFS (risk ratio [RR] = 0.74; P = .010), and OS (RR = 0.69; P = .013). Four-year DFS was 82% for the dose-dense regimens and 75% for the others. There was no difference in either DFS or OS between the concurrent and sequential schedules. There was no interaction between density and sequence. Severe neutropenia was less frequent in patients who received the dose-dense regimens. Conclusion: Dose density improves clinical outcomes significantly, despite the lower than expected number of events at this time. Sequential chemotherapy is as effective as concurrent chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1990) · Choice Reviews Online · doi:10.5860/choice.27-3338 · Cited by 35,305
Tamoxifen for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,085
Focan, C., Steinberg, S. M., Blichert-Toft, M., Forbes, J., Collins, R. D., Anderson, S., Margreiter, R., Harwood, C. S., Andersen, K., Beighton, G., et al. (1998) · PubMed · Cited by 2,146
Self-citationHenderson, I. C., Berry, D. A., Demetri, G. D., Cirrincione, C. T., Goldstein, L. J., Martino, S., Ingle, J. N., Cooper, M. R., Hayes, D. F., Tkaczuk, K. H., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.063 · Cited by 1,294
Self-citationA Gompertzian model of human breast cancer growth.
Norton, L. (1988) · PubMed · Cited by 679
Self-citationDose and Dose Intensity as Determinants of Outcome in the Adjuvant Treatment of Breast Cancer
Budman, D. R., Berry, D. A., Cirrincione, C. T., Henderson, Wood, W. C., Weiss, R. B., Ferree, C. R., Muss, H. B., Green, M. R., Norton, L., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.16.1205 · Cited by 577
Self-citationOvarian ablation in early breast cancer: overview of the randomised trials
(1996) · The Lancet · doi:10.1016/s0140-6736(96)05023-4 · Cited by 561
Devita, V. T., Young, R. C., & Canellos, G. P. (1975) · Cancer · doi:10.1002/1097-0142(197501)35:1<98::aid-cncr2820350115>3.0.co;2-b · Cited by 411
Bonadonna, G. (1995) · JAMA · doi:10.1001/jama.273.7.542 · Cited by 352
Green, D. M., Grigoriev, Y. A., Nan, B., Takashima, J. R., Norkool, P. A., D’Angio, G. J., & Breslow, N. E. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.7.1926 · Cited by 319
Cited by
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Breast Cancer Treatment: A Review
Waks, A. G., & Winer, E. P. (2019) · JAMA · doi:10.1001/jama.2018.19323 · Cited by 4,804
Self-citationGoldhirsch, A., Wood, W. C., Coates, A. S., Gelber, R. D., Thürlimann, B., & Senn, H.-J. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr304 · Cited by 3,836
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E., & Gianni, L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.66 · Cited by 3,079
A view on drug resistance in cancer
Vasan, N., Baselga, J., & Hyman, D. M. (2019) · Nature · doi:10.1038/s41586-019-1730-1 · Cited by 2,770
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S., Davidson, T., Gruber, G., & Castiglione, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq159 · Cited by 2,842
Oettle, H., Post, S., Neuhaus, P., Gellert, K., Langrehr, J., Ridwelski, K., Schramm, H., Fahlke, J., Zuelke, C., Burkart, C., et al. (2007) · JAMA · doi:10.1001/jama.297.3.267 · Cited by 2,419
Harbeck, N., & Gnant, M. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31891-8 · Cited by 2,280
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I. T., Zackrisson, S., & Senkus, E. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz173 · Cited by 2,214
Smith, T. J., Khatcheressian, J., Lyman, G. H., Ozer, H., Armitage, J. O., Balducci, L., Bennett, C. L., Cantor, S. B., Crawford, J., Cross, S. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.4451 · Cited by 1,636
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Self-citationPrimary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Senkus, E., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rutgers, E., Zackrisson, S., & Cardoso, F. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv298 · Cited by 1,597
Contradicted and Initially Stronger Effects in Highly Cited Clinical Research
Ioannidis, J. P. A. (2005) · JAMA · doi:10.1001/jama.294.2.218 · Cited by 1,465
The anti-angiogenic basis of metronomic chemotherapy
Kerbel, R. S., & Kamen, B. A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1369 · Cited by 1,397
Treatment landscape of triple-negative breast cancer — expanded options, evolving needs
Bianchini, G., De Angelis, C., Licata, L., & Gianni, L. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00565-2 · Cited by 1,382
Diaz-Montero, C. M., Salem, M. L., Nishimura, M. I., Garrett-Mayer, E., Cole, D. J., & Montero, A. J. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0523-4 · Cited by 1,215
Genome remodelling in a basal-like breast cancer metastasis and xenograft
Ding, L., Ellis, M. J., Li, S., Larson, D. E., Chen, K., Wallis, J. W., Harris, C. C., McLellan, M. D., Fulton, R. S., Fulton, L. L., et al. (2010) · Nature · doi:10.1038/nature08989 · Cited by 1,139
Goldhirsch, A., Glick, J. H., Gelber, R. D., Coates, A. S., Thürlimann, B., & Senn, H.-J. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi326 · Cited by 1,127
Aapro, M. S., Bohlius, J., Cameron, D. A., Lago, L. D., Donnelly, J. P., Kearney, N., Lyman, G. H., Pettengell, R., Tjan-Heijnen, V. C., Walewski, J., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2010.10.013 · Cited by 1,090
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
Gilbert, M. R., Wang, M., Aldape, K. D., Stupp, R., Hegi, M. E., Jaeckle, K. A., Armstrong, T. S., Wefel, J. S., Won, M., Blumenthal, D. T., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.6968 · Cited by 1,063
Chang, H. Y., Nuyten, D. S. A., Sneddon, J. B., Hastie, T., Tibshirani, R., Sørlie, T., Dai, H., He, Y. D., van't Veer, L. J., Bartelink, H., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409462102 · Cited by 981
Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer
Sparano, J. A., Wang, M., Martino, S., Jones, V., Perez, E. A., Saphner, T., Wolff, A. C., Sledge, G. W., Wood, W. C., & Davidson, N. E. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707056 · Cited by 997
Self-citationAdjuvant Docetaxel for Node-Positive Breast Cancer
Martin, M., Pienkowski, T., Mackey, J., Pawlicki, M., Guastalla, J.-P., Weaver, C., Tomiak, E., Al-Tweigeri, T., Chap, L., Juhos, E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043681 · Cited by 954
Bear, H. D., Anderson, S., Smith, R. E., Geyer, C. E., Mamounas, E. P., Fisher, B., Brown, A. M., Robidoux, A., Margolese, R., Kahlenberg, M. S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.1665 · Cited by 943
Chemotherapy‐induced neutropenia: Risks, consequences, and new directions for its management
Crawford, J., Dale, D. C., & Lyman, G. H. (2004) · Cancer · doi:10.1002/cncr.11882 · Cited by 882
Pawitan, Y., Bjöhle, J., Amler, L., Borg, A.-L., Egyhazi, S., Hall, P., Han, X., Holmberg, L., Huang, F., Klaar, S., et al. (2005) · Breast Cancer Research · doi:10.1186/bcr1325 · Cited by 831
Epithelial-mesenchymal transition in cancer development and its clinical significance
Iwatsuki, M., Mimori, K., Yokobori, T., Ishi, H., Beppu, T., Nakamori, S., Baba, H., & Mori, M. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2009.01419.x · Cited by 780
Breast Cancer Before Age 40 Years
Anders, C. K., Johnson, R., Litton, J., Phillips, M., & Bleyer, A. (2009) · Seminars in Oncology · doi:10.1053/j.seminoncol.2009.03.001 · Cited by 791
Womer, R. B., West, D. C., Krailo, M. D., Dickman, P. S., Pawel, B. R., Grier, H. E., Marcus, K., Sailer, S., Healey, J. H., Dormans, J. P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.5703 · Cited by 757
Berry, D. A., Cirrincione, C., Henderson, I. C., Citron, M. L., Budman, D. R., Goldstein, L. J., Martino, S., Perez, E. A., Muss, H. B., Norton, L., et al. (2006) · JAMA · doi:10.1001/jama.295.14.1658 · Cited by 731
Self-citationKuderer, N. M., Dale, D. C., Crawford, J., & Lyman, G. H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8823 · Cited by 720
Goldhirsch, A., Wood, W. C., Gelber, R. D., Coates, A. S., Thürlimann, B., & Senn, H.-J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.576 · Cited by 697
Triple-negative breast cancer—current status and future directions
Gluz, O., Liedtke, C., Gottschalk, N., Pusztai, L., Nitz, U., & Harbeck, N. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp492 · Cited by 687
Repopulation of cancer cells during therapy: an important cause of treatment failure
Kim, J. J., & Tannock, I. F. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1650 · Cited by 686
The mathematics of cancer: integrating quantitative models
Altrock, P. M., Liu, L. L., & Michor, F. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4029 · Cited by 685
Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Moran, M. S., Abraham, J., Abramson, V., Aft, R., Agnese, D., Allison, K. H., Anderson, B., Bailey, J., Burstein, H. J., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.0035 · Cited by 664
Self-citationSchnipper, L. E., Smith, T. J., Raghavan, D., Blayney, D. W., Ganz, P. A., Mulvey, T. M., & Wollins, D. S. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.8375 · Cited by 649
Biology, Metastatic Patterns, and Treatment of Patients with Triple-Negative Breast Cancer
Anders, C. K., & Carey, L. A. (2009) · Clinical Breast Cancer · doi:10.3816/cbc.2009.s.008 · Cited by 625
HER2 and Response to Paclitaxel in Node-Positive Breast Cancer
Hayes, D. F., Thor, A. D., Dressler, L. G., Weaver, D., Edgerton, S., Cowan, D., Broadwater, G., Goldstein, L. J., Martino, S., Ingle, J. N., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071167 · Cited by 608
Self-citationJones, S., Holmes, F. A., O'Shaughnessy, J., Blum, J. L., Vukelja, S. J., McIntyre, K. J., Pippen, J. E., Bordelon, J. H., Kirby, R. L., Sandbach, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.4028 · Cited by 588
Self-citationOverview of Breast Cancer Therapy
Moo, T.-A., Sanford, R., Dang, C., & Morrow, M. (2018) · PET Clinics · doi:10.1016/j.cpet.2018.02.006 · Cited by 551
Aapro, M. S., Cameron, D. A., Pettengell, R., Bohlius, J., Crawford, J., Ellis, M., Kearney, N., Lyman, G. H., Tjan-Heijnen, V. C., Walewski, J., et al. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.05.002 · Cited by 539
Taxanes, microtubules and chemoresistant breast cancer
McGrogan, B. T., Gilmartin, B., Carney, D. N., & McCann, A. (2008) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2007.10.004 · Cited by 535
Ganz, P. A., Kwan, L., Stanton, A. L., Krupnick, J. L., Rowland, J. H., Meyerowitz, B. E., Bower, J. E., & Belin, T. R. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh060 · Cited by 505
Simeoni, M., Magni, P., Cammia, C., De Nicolao, G., Croci, V., Pesenti, E., Germani, M., Poggesi, I., & Rocchetti, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2524 · Cited by 506
Breast Cancer Treatments: Updates and New Challenges
Burguin, A., Diorio, C., & Durocher, F. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080808 · Cited by 488
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Senkus, E., Kyriakides, S., Penault-Llorca, F., Poortmans, P., Thompson, A., Zackrisson, S., & Cardoso, F. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt284 · Cited by 479
Antiangiogenic Therapy: A Universal Chemosensitization Strategy for Cancer?
Kerbel, R. S. (2006) · Science · doi:10.1126/science.1125950 · Cited by 466
Lyman, G. H., Dale, D. C., & Crawford, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.002 · Cited by 464
Triple-Negative Breast Cancer: Risk Factors to Potential Targets
Schneider, B. P., Winer, E. P., Foulkes, W. D., Garber, J., Perou, C. M., Richardson, A., Sledge, G. W., & Carey, L. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1208 · Cited by 437
Self-citationGreen, M. C., Buzdar, A. U., Smith, T., Ibrahim, N. K., Valero, V., Rosales, M. F., Cristofanilli, M., Booser, D. J., Pusztai, L., Rivera, E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.232 · Cited by 419
Adjuvant Chemotherapy in Older and Younger Women With Lymph Node–Positive Breast Cancer
Muss, H. B. (2005) · JAMA · doi:10.1001/jama.293.9.1073 · Cited by 418
Self-citationBreast cancer: an up‐to‐date review and future perspectives
Hong, R., & Xu, B. (2022) · Cancer Communications · doi:10.1002/cac2.12358 · Cited by 407
Bodai, B. I., & Tuso, P. (2015) · The Permanente Journal · doi:10.7812/tpp/14-241 · Cited by 397
Dietz, J. R., Moran, M. S., Isakoff, S. J., Kurtzman, S. H., Willey, S. C., Burstein, H. J., Bleicher, R. J., Lyons, J. A., Sarantou, T., Baron, P. L., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05644-z · Cited by 393
Self-citationImpact of Chemotherapy Dose Intensity on Cancer Patient Outcomes
Lyman, G. H. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0009 · Cited by 383
Progress in adjuvant chemotherapy for breast cancer: an overview
Anampa, J., Makower, D., & Sparano, J. A. (2015) · BMC Medicine · doi:10.1186/s12916-015-0439-8 · Cited by 373
Cardiotoxicity of Cancer Therapy
Floyd, J. D., Nguyen, D. T., Lobins, R. L., Bashir, Q., Doll, D. C., & Perry, M. C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.789 · Cited by 372
G-CSF and GM-CSF in Neutropenia
Mehta, H. M., Malandra, M., & Corey, S. J. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500861 · Cited by 363
Adjuvant Dose-Dense Chemotherapy in Breast Cancer: Standard of Care in High-Risk Patients
Möbus, V. (2016) · Breast Care · doi:10.1159/000444004 · Cited by 354
Triple-Negative Breast Cancer: Role of Specific Chemotherapy Agents
Isakoff, S. J. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181d24ff7 · Cited by 348
Lewis, I. J., Nooij, M. A., Whelan, J., Sydes, M. R., Grimer, R., Hogendoorn, P. C. W., Memon, M. A., Weeden, S., Uscinska, B. M., van Glabbeke, M., et al. (2007) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djk015 · Cited by 346
Zsiros, J., Brugieres, L., Brock, P., Roebuck, D., Maibach, R., Zimmermann, A., Childs, M., Pariente, D., Laithier, V., Otte, J.-B., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70272-9 · Cited by 345
Muss, H. B., Berry, D. A., Cirrincione, C., Budman, D. R., Henderson, I. C., Citron, M. L., Norton, L., Winer, E. P., & Hudis, C. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.9710 · Cited by 339
Self-citationClinical implications of cancer self-seeding
Comen, E., Norton, L., & Massagué, J. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.64 · Cited by 312
Self-citationHand-Foot Syndrome After Dose-Dense Adjuvant Chemotherapy for Breast Cancer: A Case Series
Bardia, A., Loprinzi, C. L., & Goetz, M. P. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.1143 · Cited by 312
Cardiac Toxicity in Breast Cancer Survivors: Review of Potential Cardiac Problems
Bird, B. R. J. H., & Swain, S. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1033 · Cited by 307
Older Female Cancer Patients: Importance, Causes, and Consequences of Undertreatment
Bouchardy, C., Rapiti, E., Blagojevic, S., Vlastos, A.-T., & Vlastos, G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.4208 · Cited by 306
PANoptosis: Mechanisms, biology, and role in disease
Sun, X., Yang, Y., Meng, X., Li, J., Liu, X., & Liu, H. (2024) · Immunological Reviews · doi:10.1111/imr.13279 · Cited by 305
Cardoso, F., Loibl, S., Pagani, O., Graziottin, A., Panizza, P., Martincich, L., Gentilini, O., Peccatori, F., Fourquet, A., Delaloge, S., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.10.004 · Cited by 304
Effect of Cytotoxic Chemotherapy on Markers of Molecular Age in Patients With Breast Cancer
Sanoff, H. K., Deal, A. M., Krishnamurthy, J., Torrice, C., Dillon, P., Sorrentino, J., Ibrahim, J. G., Jolly, T. A., Williams, G., Carey, L. A., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju057 · Cited by 283
Self-citationBlum, J. L., Flynn, P. J., Yothers, G., Asmar, L., Geyer, C. E., Jacobs, S. A., Robert, N. J., Hopkins, J. O., O'Shaughnessy, J. A., Dang, C. T., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.4147 · Cited by 294
Long-term toxic effects of adjuvant chemotherapy in breast cancer
Azim, H. A., de Azambuja, E., Colozza, M., Bines, J., & Piccart, M. J. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq683 · Cited by 292
Undertreatment of Obese Women Receiving Breast Cancer Chemotherapy
Griggs, J. J., Sorbero, M. E. S., & Lyman, G. H. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.11.1267 · Cited by 289
Battling Chemoresistance in Cancer: Root Causes and Strategies to Uproot Them
Ramos, A., Sadeghi, S., & Tabatabaeian, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179451 · Cited by 289
Nyman, D. W., Campbell, K. J., Hersh, E., Long, K., Richardson, K., Trieu, V., Desai, N., Hawkins, M. J., & Von Hoff, D. D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.6148 · Cited by 286
Hershman, D., Neugut, A. I., Jacobson, J. S., Wang, J., Tsai, W.-Y., McBride, R., Bennett, C. L., & Grann, V. R. (2007) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djk028 · Cited by 279
Past, Present, and Future Challenges in Breast Cancer Treatment
Sledge, G. W., Mamounas, E. P., Hortobagyi, G. N., Burstein, H. J., Goodwin, P. J., & Wolff, A. C. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.4139 · Cited by 277
Benson, J. R., Jatoi, I., Keisch, M., Esteva, F. J., Makris, A., & Jordan, V. C. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60316-0 · Cited by 261
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S., Davidson, T., Gruber, G., & Cardoso, F. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr371 · Cited by 256
Evolution of acquired resistance to anti-cancer therapy
Foo, J., & Michor, F. (2014) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2014.02.025 · Cited by 254
Triple-Negative Breast Cancer: Epidemiology and Management Options
Dawood, S. (2010) · Drugs · doi:10.2165/11538150-000000000-00000 · Cited by 253
The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer
Straver, M. E., Glas, A. M., Hannemann, J., Wesseling, J., van de Vijver, M. J., Rutgers, E. J. T., Vrancken Peeters, M.-J. T. F. D., van Tinteren, H., van‘t Veer, L. J., & Rodenhuis, S. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0333-1 · Cited by 252
Monk, J. P., Phillips, G., Waite, R., Kuhn, J., Schaaf, L. J., Otterson, G. A., Guttridge, D., Rhoades, C., Shah, M., Criswell, T., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.2838 · Cited by 179
Akita, H., Doki, Y., Miyata, H., Hirao, T., Yano, M., Takachi, K., Miyashiro, I., Sasaki, Y., Ishikawa, O., Ohigashi, H., et al. (2006) · Journal of Surgical Oncology · doi:10.1002/jso.20501 · Cited by 28
Metadata
- Authors
- Citron, M. L., Berry, D. A., Cirrincione, C., Hudis, C., Winer, E. P., Gradishar, W. J., Davidson, N. E., Martino, S., Livingston, R., Ingle, J. N., Perez, E. A., Carpenter, J., Hurd, D., Holland, J. F., Smith, B. L., Sartor, C. I., Leung, E. H., Abrams, J., Schilsky, R. L., Muss, H. B., & Norton, L.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-04-15
- Volume
- 21
- Issue
- 8
- Pages
- 1431-1439
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2101760255
- Cited by
- 1,564
- References
- 15
- FWCI
- 45.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.